SCN8A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL91269	0.50	8/20
SCHEMBL184153	0.50	8/20
SCHEMBL184154	0.50	8/20
SCHEMBL64093	0.48	5/20
SCHEMBL77362	0.37	4/20
SCHEMBL78591	0.43	3/20
SCHEMBL137964	0.43	3/20
SCHEMBL73389	0.40	3/20
SCHEMBL183941	0.60	2/20
SCHEMBL183942	0.60	2/20
Hydrochloric Acid (SCHEMBL155367)	0.56	2/20
SCHEMBL147753	0.54	2/20
SCHEMBL167871	0.43	2/20
SCHEMBL171901	0.43	2/20
SCHEMBL275414	0.41	2/20
SCHEMBL279816	0.41	2/20
SCHEMBL256845	0.40	2/20
SCHEMBL257609	0.37	2/20
Mexiletine (SCHEMBL16081)	1.00	1/20
(R)-Mexiletine (SCHEMBL16082)	1.00	1/20

Clinical trials — most relevant to SCN8A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations	PHASE4	COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome	PHASE1/PHASE2	RECRUITING
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8	EARLY_PHASE1	COMPLETED
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Probing the Role of Sodium Channels in Painful Neuropathies	nan	UNKNOWN
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A	nan	COMPLETED
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients	nan	COMPLETED
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED
Painful Channelopathies Study	nan	UNKNOWN
Genetic Study of Familial Epilepsy	nan	COMPLETED
Drug Resistant Epilepsy: Clinical and Genetic Study	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCN8A binder may also engage these)

Protein	Name	Similarity
O88420	—	1.000	O88420 →
SCN2A	Sodium channel protein type 2 subunit alpha	1.000	landscape →
P04775	—	1.000	P04775 →
SCN3A	Sodium channel protein type 3 subunit alpha	1.000	landscape →
Q9WTU3	—	1.000	Q9WTU3 →
Q28644	—	1.000	Q28644 →
B1AWN6	—	1.000	B1AWN6 →
Q62205	—	1.000	Q62205 →
O08562	—	1.000	O08562 →
A2ASI5	—	1.000	A2ASI5 →
P08104	—	1.000	P08104 →
A2APX8	—	1.000	A2APX8 →
P15390	—	0.999	P15390 →
SCN1A	Sodium channel protein type 1 subunit alpha	0.999	landscape →
Q62968	—	0.999	Q62968 →
SCN9A	Sodium channel protein type 9 subunit alpha	0.998	landscape →
Q6QIY3	—	0.997	Q6QIY3 →
P04774	—	0.997	P04774 →
P15389	—	0.997	P15389 →
Q2XVR7	—	0.997	Q2XVR7 →
Q2XVR3	—	0.996	Q2XVR3 →
P02719	—	0.996	P02719 →
Q9JJV9	—	0.996	Q9JJV9 →
Q9ER60	—	0.995	Q9ER60 →
Q20JQ7	—	0.995	Q20JQ7 →
Q28371	—	0.994	Q28371 →
SCN5A	Sodium channel protein type 5 subunit alpha	0.993	landscape →
SCN10A	Sodium channel protein type 10 subunit alpha	0.993	landscape →
P35500	—	0.993	P35500 →
Q2XVR6	—	0.993	Q2XVR6 →